Skip to main content
Marvel Biosciences Corp. logo

Marvel Biosciences Corp. — Investor Relations & Filings

Ticker · MRVL ISIN · CA57384M1077 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 255 across all filing types
Latest filing 2021-09-17 Regulatory Filings
Country CA Canada
Listing TSXV MRVL

About Marvel Biosciences Corp.

https://marvelbiotechnology.com/

Marvel Biosciences Corp. is a pre-clinical stage biotechnology company specializing in the discovery and development of transformative treatments for complex neurological and neurodevelopmental disorders, including Autism Spectrum Disorder, Rett Syndrome, and Fragile X Syndrome. The company's core strategy involves chemical innovation to create synthetic derivatives of existing approved molecules. This drug redevelopment approach leverages established mechanisms to accelerate development and reduce risk. Its lead candidate, MB-204, is a patented synthetic derivative that has demonstrated preclinical efficacy across these target indications and is currently advancing toward first-in-human studies.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a news release announcing Marvel Biosciences Corp.'s upcoming presentation at an international conference. It provides background on the company, its lead compound, and contact information. There are no financial statements, regulatory filings, voting results, or management changes. The content is promotional and informational about a conference presentation, not a financial report or regulatory filing. Therefore, it does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is best classified as a general Regulatory Filing (RNS) since it is a public announcement that does not fit other specific categories.
2021-09-17 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a news release announcing that Marvel Biosciences Corp. has retained Virtus Advisory Group to provide corporate communications services. It details the consulting contract terms, stock options, and background information about both companies. There is no financial data, no report attached or referenced as being published, no regulatory certification, no voting results, no management changes, no earnings or interim report, no merger or acquisition activity, and no other specific report content. This is a corporate announcement about a consulting engagement and stock option grant, which does not fit into financial report categories or regulatory filings related to financial performance or governance changes. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2021-08-03 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a news release announcing a manufacturing agreement for the company's lead asset MB-204. It contains no financial statements, no regulatory filings, no voting results, no management or board changes, no earnings data, and no detailed financial or operational report. It is a corporate announcement about a business milestone and partnership, typical of a press release. The document length is 7612 characters, which is sufficient for a detailed announcement but it does not contain financial data or report content. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a general Regulatory Filing (RNS) as a miscellaneous corporate announcement that does not fit other categories.
2021-07-21 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a news release announcing the completion of a qualifying transaction involving a reverse takeover, a name change, and a private placement financing. It details the acquisition structure, capital structure, board reconstitution, and financing proceeds. The document does not contain financial statements or detailed financial performance data. It primarily serves as an announcement of corporate actions and financing updates related to the transaction. There is no indication that this is a full annual or interim report, audit report, or earnings release. The focus on acquisition completion and financing conditions aligns with Capital/Financing Update filings. Therefore, the document is best classified as a Capital/Financing Update (CAP).
2021-07-08 English
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Regulatory Filings
2021-06-19 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate by the CFO of Alphanco Venture Corp. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended April 30, 2021. The document is primarily an officer certification letter confirming the accuracy and completeness of the interim filings, without containing actual financial data or substantive financial analysis itself. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) they reference. The document length is short (2978 characters), and it is clearly a certification rather than the report itself.
2021-06-12 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.